Cantel Medical Corp.

Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis
  • TickerCMD
  • ISINUS1380981084
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
Valens Research

Valens Equity Insights and Inflections - 2021 04 20

Current market expectations for GTII are for profitability to reverse impressive gains, and growth to remain high but slow significantly. Markets expect UAFRS-based ROA (Uniform ROA or ROA') to drop from a forecasted 30% in 2021 to 17% going forward, with growth falling by more than half. However, the company is primed to ride the tailwinds of cannabis legalization, which may lead to the market opportunity for Green Thumb to more than triple in the coming years. On top of that, the company has positioned itself well with a sound strategy for growing high returns thanks to its branded produc...

Valens Research

CMD - Embedded Expectations Analysis - 2021 04 14

Cantel Medical Corp. (CMD:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 22.0x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, and management may have concerns about the pace of elective procedure recovery, Dental segment margins, and EPS and operating profit growth Specifically, management may lack confidence in their ability to sustain EPS growth, generate operating profit growth, and maintain wallet share gains with the complete circle of protection portfolio. In addition, they may have concerns about t...

CANTEL MEDICAL CORP. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CANTEL MEDICAL CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 26, 2021, the closing price was USD 80.52 and its target price was estimated at USD 42.24.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland

Monthly Insider Special Screens: April 1, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Energy related names are reversing price and RS downtrends. (ex. DRQ, OII, AROC, and CKH) • A few banks and asset managers are inflecting positively or within uptrends. (ex. C, BRKL, VLY, FCF, LM, and INTL) • The healthcare Sector has a number of names inflecting bullishly (ex. CUTR, CMD, IART, CCRN, CRVL, MGLN, PGNX, ANIK, ILMN, IQV, and ANIP)

Valens Research

Valens Equity Insights and Inflections - 2021 04 20

Current market expectations for GTII are for profitability to reverse impressive gains, and growth to remain high but slow significantly. Markets expect UAFRS-based ROA (Uniform ROA or ROA') to drop from a forecasted 30% in 2021 to 17% going forward, with growth falling by more than half. However, the company is primed to ride the tailwinds of cannabis legalization, which may lead to the market opportunity for Green Thumb to more than triple in the coming years. On top of that, the company has positioned itself well with a sound strategy for growing high returns thanks to its branded produc...

Valens Research

CMD - Embedded Expectations Analysis - 2021 04 14

Cantel Medical Corp. (CMD:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 22.0x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, and management may have concerns about the pace of elective procedure recovery, Dental segment margins, and EPS and operating profit growth Specifically, management may lack confidence in their ability to sustain EPS growth, generate operating profit growth, and maintain wallet share gains with the complete circle of protection portfolio. In addition, they may have concerns about t...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland

Monthly Insider Special Screens: April 1, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CANTEL MEDICAL CORP. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CANTEL MEDICAL CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 26, 2021, the closing price was USD 80.52 and its target price was estimated at USD 42.24.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch